Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension

Journal of Pharmacological and Toxicological Methods

Volumn 57, Issue 3, 2008, Pages 212-219

  Bertera, Facundo M ^a   Mayer, Marcos A ^a   Opezzo, Javier A W ^a   Taira, Carlos A ^a   Höcht, Christian ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Aortic coarctation; Chronotropic effect; Hypotensive effect; Microdialysis; Pharmacokinetic pharmacodynamic modeling; Plasma pharmacokinetics; Verapamil

Indexed keywords

VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; MALE; MICRODIALYSIS; NONHUMAN; RAT; RENOVASCULAR HYPERTENSION;

ANIMALS; AORTA; AORTIC COARCTATION; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HYPERTENSION, RENOVASCULAR; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; VERAPAMIL;

RATTUS;

EID: 44449161926     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2008.03.002     Document Type: Article

References (44)

1. Aarons L., Baxter C., and Gupta S. Pharmacodynamics of controlled release verapamil in patients with hypertension: An analysis using spline functions. Biopharmaceutics & Drug Disposition 25 (2004) 219-225
2. Csajka C., and Verotta D. Pharmacokinetic-pharmacodynamic modeling: History and perspectives. Journal of Pharmacokinetics and Pharmacodynamics 33 (2006) 227-279
3. Badyal D.K., Lata H., and Dadhich A.P. Animal models of hypertension and effect of drugs. Indian Journal of Pharmacology 35 (2003) 349-362
4. Bertera F.M., Mayer M.A., Opezzo J.A.W., Taira C.A., Bramuglia G.F., and Höcht C. Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: A microdialysis study. Journal of Pharmacological and Toxicological Methods 56 (2007) 290-299
5. D'Argenio D.Z., and Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software (1997), Biomedical Simulations Resource, Los Angeles
6. Donnelly R., Elliott H.L., and Meredith P.A. Antihypertensive drugs: Individualized analysis and clinical relevance of kinetic-dynamic relationships. Pharmacology & Therapeutics 53 (1992) 67-79
7. Donnelly R., Reid J.L., Meredith P.A., Ahmed J.H., and Elliott H.L. Factors determining the response to calcium antagonists in hypertension. Journal of Cardiovascular Pharmacology 12 Suppl 6 (1988) S109-S113
8. Echizen H., and Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clinical Pharmacokinetics 11 (1986) 425-449
9. Eichelbaum M., Somogyi A., von Unruh G.E., and Dengler H.J. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of d,l-verapamil using stable isotope-labelled verapamil. European Journal of Clinical Pharmacology 19 (1981) 133-137
10. Elliot L.A., and Jamali F. Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. The Journal of Pharmacology and Experimental Therapeutics 291 (1999) 188-193
11. Gibaldi M., and Perrier D. Pharmacokinetics. 2nd ed. (1982), Marcel Dekker Inc, New York
12. Gupta S., Modi N.B., Sathyan G., Ho Pl P.L., and Aarons L. Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. Biopharmaceutics & Drug Disposition 23 (2002) 17-31
13. Hamann S.R., Blouin R.A., and McAllister Jr. R.G. Clinical pharmacokinetics of verapamil. Clinical Pharmacokinetics 9 (1984) 26-41
14. Harder S., Rietbrock S., and Thürmann P. Concentration/effect analysis of verapamil: Evaluation of different approaches. International Journal of Clinical Pharmacology, Therapy and Toxicology 31 (1993) 469-475
15. Harder S., Thürmann P., and Rietbrock N. Concentration/effect analysis of antihypertensive drugs. American Journal of Therapeutics 1 (1994) 116-124
16. Harder S., Thürmann P., Siewert M., Blume H., Rietbrock N., van der Kleijn J., et al. Concentration/effect relationship and enantioselective analysis of verapamil in hypertensive patients. Journal of Cardiovascular Pharmacology 19 (1992) 665-669
17. Höcht C., Di Verniero C., Opezzo J.A.W., and Taira C.A. Application of the microdialysis technique for the pharmacokinetic-pharmacodynamic (PK-PD) modeling of beta-blockers. Journal of Pharmacological and Toxicological Methods 52 (2005) 244-250
18. Höcht C., Opezzo J.A.W., and Taira C.A. Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. Journal of Pharmaceutical and Biomedical Analysis 31 (2003) 1105-1113
19. Höcht C., Opezzo J.A.W., and Taira C.A. Microdialysis in drug discovery. Current Drug Discovery Technologies 1 (2004) 269-285
20. Höcht C., Opezzo J.A.W., and Taira C.A. Applicability of reverse microdialysis in pharmacological and toxicological studies. Journal of Pharmacological and Toxicological Methods 55 (2007) 3-15
21. Hoffman B.B. Therapy of hypertension. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11 edition (2006), Mc Graw Hill, New York 845-868
22. Keefe D.L., Yee Y.G., and Kates R.E. Verapamil protein binding in patients and in normal subjects. Clinical Pharmacology & Therapeutics 29 (1981) 21-26
23. Loch J.M., Potter J., and Bachmann K.A. The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo. Pharmacology 50 (1995) 146-153
24. Manitpisitkul P., and Chiou W.L. Intravenous verapamil kinetics in rats: Marked arteriovenous concentration difference and comparison with humans. Biopharmaceutics & Drug Disposition 14 (1993) 555-566
25. McAllister Jr. R.G., Schloemer G.L., and Hamann S.R. Kinetics and dynamics of calcium entry antagonists in systemic hypertension. American Journal of Cardiology 57 (1986) 16D-21D
26. Meneguz A., Fortuna S., Lorenzini P., and Volpe M.T. Influence of rethane and ketamine on rat hepatic cytochrome P450 in vivo. Experimental and Toxicological Pathology 51 (1999) 392-396
27. Meredith P.A. Clinical relevance of optimal pharmacokinetics in the treatment of hypertension. Journal of Hypertension 15 suppl 5 (1997) S27-S31
28. Meredith P.A., Elliott H.L., Pasanisi F., Kelman A.W., Sumner D.J., and Reid J.L. Verapamil pharmacokinetics and apparent hepatic and renal blood flow. British Journal of Clinical Pharmacology 20 (1985) 101-106
29. Mori Y., Hanada K., Mori T., Tsukahara Y., Hashiguchi M., and Ogata H. Stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil in rabbits. Biological & Pharmaceutical Bulletin 24 (2001) 806-810
30. Novikov Y.V., Shormanov S.V., and Kulikov S.V. Reversibility of changes in hepatic vessels after correction of experimental aortic coarctation. Bulletin of Experimental Biology and Medicine 141 (2006) 479-482
31. Pérez-Urizar J., Granados-Soto V., Flores-Murrieta F.J., and Castañeda-Hernández G. Pharmacokinetic-pharmacodynamic modeling: Why?. Archives of Medical Research 31 (2000) 539-545
32. Resnick L.M. Calcium metabolism, renin activity, and the antihypertensive effects of calcium channel blockade. The American Journal of Medicine 15 (1986) 6-14
33. Resnick L.M. Calcium metabolism in the pathophysiology and treatment of clinical hypertension. American Journal of Hypertension 2 6 Pt 2 (1989) 179S-185S
34. Rosenthal T. Drug therapy of renovascular hypertension. Drugs 45 (1993) 895-909
35. Rojo-Ortega J.M., and Genest J. A method for production of experimental hypertension in rats. Canadian Journal of Physiology and Pharmacology 46 (1968) 883-885
36. Santos C.M., Pontieri V., Leomil Neto M., and Michelini L.C. Losartan improves baroreflex control of heart rate of coarcted hypertensive rats. American Journal of Physiology 269 (1995) H812-H818
37. Schoemaker R.C., van Gerven J.M.A., and Cohen A.F. Estimating potency for the Emax-model without attaining maximal effects. Journal of Pharmacokinetics and Biopharmaceutics 26 (1998) 581-593
38. Shormanov S.V., and Kulikov S.V. Morphological changes of hepatic vessels in experimental aortal coarctation and after its elimination. Morfologiia 124 (2003) 61-66
39. Ståhle L. Pharmacokinetic estimations from microdialysis data. European Journal of Clinical Pharmacology 43 (1992) 289-294
40. Storm D.S., and Webb R.C. Contractile responses to Bay K 8644 in rats with coarctation-induced hypertension. Proceedings of the Society for Experimental Biology and Medicine 203 (1993) 92-99
41. Toutain P.L. Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. AAPS Pharmaceutical Sciences 4 (2002) 1-29
42. Woodcock B.G., Schulz W., Kober G., and Rietbrock N. Direct determination of hepatic extraction of verapamil in cardiac patients. Clinical Pharmacology & Therapeutics 30 (1981) 52-56
43. Yang F., and Nickerson P.A. Direct correlation between calcium content and blood pressure: A study of aortic coarctation in rats. Proceedings of the Society for Experimental Biology and Medicine 189 (1988) 206-210
44. Zawada Jr. E.T., and Johnson M. Calcium chelation and calcium-channel blockade in anesthetized acute renovascular hypertensive dogs. Mineral and Electrolyte Metabolism 10 (1984) 366-370